SCHEMBL483384

SCHEMBL483384

CNc1ccc(Br)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.46
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ALOX12 P18054 3/20 0.46
TP53 P04637 2/20 0.46
HPGD P15428 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 4/20 0.42
POLB P06746 1/20 0.42
KDM4E B2RXH2 1/20 0.42
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17421094 0.98 LMNA (0.45) LMNANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL12524550 0.84 ALDH1A1 (0.45) LMNANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL9231547 0.82 IDO1 (0.39) LMNANPC1RAB9AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL28510818 0.80 IDO1 (0.38) LMNANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL19267221 0.79 LMNA (0.51) LMNANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL12190764 0.78 APP (0.37) LMNARAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL2088461 0.77 LMNA (0.46) LMNANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL154208 0.77 CA1 (0.50) LMNANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL12883439 0.77 LMNA (0.42) LMNANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL741149 0.77 KDM4E (0.46) LMNANPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104620104-B Affinity Reagents for Protein Purification 非凡食品有限公司 2017-03-01 CN claimed
WO-2025137606-A1 (HETERO)ARYL NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY, INC. (US) 2025-06-26 WO disclosed
CN-114716381-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114605327-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114573510-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-02-25 CN disclosed
CN-114302874-B Indole carboxamide derivatives and pharmaceutical compositions containing the same 国际药品株式会社 2025-02-25 CN disclosed
CN-114591242-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-01-07 CN disclosed
CN-114634447-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-11-15 CN disclosed
CN-113636978-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 CN disclosed
CN-113603645-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 CN disclosed
US-20100239496-A1 Imaging agents for detecting neurological disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-23 US disclosed
WO-2010051206-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-05-06 WO disclosed
CN-101641093-A Imidazotriazines and imidazopyrimidines as kinase inhibitors INCYTE CORP US 2010-02-03 CN disclosed
CN-101538268-A Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same PFIZER 2009-09-23 CN disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
WO-2008065503-A1 (R) -5-METHYL-4, 5-DIHYDRO- PYRAZOLE-1, 5-DICARBOXYLIC ACID 1- [ ( 4 -CHLOROPHENYL) AMIDE 5-{ [2-FLUORO-4- (2-OXO-2H-PYRIDIN-1-YL) -PHENYL]AMIDE) AS A FACTOR XA INHIBITOR PFIZER PRODUCTS INC. (US) 2008-06-05 WO disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
CN-101006092-A Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and therapeutic agents using the same PFIZER (US) 2007-07-25 CN disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 LMNA 4594/4885NPC1 3130/4885RAB9A 3153/4885
US-20100239496-A1 Imaging agents for detecting neurological disorders MAPT, APP, PSEN1 LMNA 991/4885NPC1 68/4885RAB9A 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.